Showing results (11-20 of 128) with videos related to
Sort By:
Pageof 13
The American Journal of the Medical Sciences|October 16, 2004
Recombinant human activated protein C in sepsis: assessing its clinical useMichael Haley, Xizhong Cui, Peter C Minneci, et al.Current Opinion in Infectious Diseases|May 29, 2004
Activated protein C in sepsis: emerging insights regarding its mechanism of action and clinical effectivenessMichael Haley, Xizhong Cui, Peter C Minneci, et al.Critical Care and Resuscitation : Journal of the Australasian Academy of Critical Care Medicine|May 12, 2020
Comparative effectiveness research in critically ill patients: risks associated with mischaracterising usual careWillard N Applefeld, Jeffrey Wang, Harvey G Klein, et al.Journal of Thoracic Disease|March 10, 2020
Driving blind: instituting SEP-1 without high quality outcomes dataJeffrey Wang, Jeffrey R Strich, Willard N Applefeld, et al.The Journal of Infectious Diseases|February 3, 2006
Effective dosing of lipid A analogue E5564 in rats depends on the timing of treatment and the route of Escherichia coli infectionSteven B Solomon, Xizhong Cui, Eric Gerstenberger, et al.Critical Care Medicine|August 8, 2014
Tidal volume and plateau pressure use for acute lung injury from 2000 to present: a systematic literature reviewDharmvir S Jaswal, Janice M Leung, Junfeng Sun, et al.Critical Care and Resuscitation : Journal of the Australasian Academy of Critical Care Medicine|December 4, 2023
Modeling current practices in critical care comparative effectiveness researchWillard N Applefeld, Jeffrey Wang, Irene Cortés-Puch, et al.Clinical Trials (London, England)|August 24, 2023
Controls, comparator arms, and designs for critical care comparative effectiveness research: It's complicatedVerity J Ford, Harvey G Klein, Robert L Danner, et al.Anesthesiology|June 27, 2003
Protection with antibody to tumor necrosis factor differs with similarly lethal Escherichia coli versus Staphylococcus aureus pneumonia in ratsWaheedullah Karzai, Xizhong Cui, Bjoern Mehlhorn, et al.Shock (Augusta, Ga.)|February 19, 2005
Prophylactic high-dose N(omega)-monomethyl-L-arginine prevents the late cardiac dysfunction associated with lethal tumor necrosis factor-alpha challenge in dogsJonathan Sevransky, R William Vandivier, Eric Gerstenberger, et al.Pageof 13